← Back to Analyst Consensus 
OVID Buy
Ovid Therapeutics Inc.
Current Price —
Implied Upside —
Analysts 16
30-Day Momentum
▲ 4 upgrades / ▼ 0 downgrades / 0 reiterations from 3 firms
Next Earnings
Nov 11, 2026 (16 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 15, 2026 | Wolfe Research | initiate | — → Outperform | — | 53% |
| Oct 9, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| Oct 6, 2026 | Guggenheim | initiate | — → Buy | — | 52% |
| Oct 5, 2026 | Guggenheim | initiate | — → Buy | — | 52% |
| Sep 11, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Aug 3, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Apr 15, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Apr 9, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 26, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Mar 20, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Dec 22, 2025 | LifeSci Capital | initiate | — → Outperform | $4 | 57% |
| Dec 22, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $2 | 44% |
| Dec 11, 2025 | Roth Capital | initiate | — → Buy | $3 | 53% |
| Nov 24, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $2 | 44% |
| Nov 17, 2025 | Leerink Partners | initiate | — → Outperform | $5 | 51% |
| May 27, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $1.5 | 44% |
| Mar 24, 2025 | BTIG | maintain | Buy → Buy | $4 | 52% |
| Mar 24, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $2 | 44% |
| Mar 12, 2025 | Wedbush | maintain | Outperform → Outperform | $3 | 58% |
| Jan 29, 2025 | Oppenheimer | upgrade | Perform → Outperform | $4 | 52% |
| Dec 4, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $3 | 44% |
| Sep 30, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $3 | 44% |
| Aug 19, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $3 | 44% |
| Jul 26, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $3 | 44% |
| Jul 2, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $3 | 44% |
| Jun 18, 2024 | BTIG | maintain | Buy → Buy | $5 | 52% |
| Jun 18, 2024 | B. Riley Securities | maintain | Buy → Buy | $3 | 55% |
| Jun 18, 2024 | Citigroup | maintain | Neutral → Neutral | $1.2 | 54% |
| Jun 18, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $3 | 44% |
| May 16, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| May 7, 2024 | Citigroup | maintain | Neutral → Neutral | $3.5 | 54% |
| Apr 30, 2024 | B. Riley Securities | initiate | — → Buy | $9 | 55% |
| Apr 29, 2024 | HC Wainwright & Co. | initiate | — → Buy | $9 | 44% |
| Apr 5, 2024 | Wedbush | initiate | — → Outperform | $8 | 58% |
| Dec 21, 2023 | BTIG | initiate | — → Buy | $11 | 52% |
| Jun 14, 2023 | JonesTrading | initiate | — → Buy | $6 | 75% |
| May 2, 2023 | Ladenburg Thalmann | reiterate | — → Buy | $7 | 45% |
| Aug 29, 2022 | Citigroup | maintain | — → Neutral | $2.5 | 54% |
| May 20, 2022 | Citigroup | maintain | — → Neutral | $2.4 | 54% |
| Aug 25, 2021 | Citigroup | maintain | — → Neutral | $4 | 54% |
| Apr 20, 2021 | Cantor Fitzgerald | downgrade | Overweight → Neutral | $4 | 50% |
| Dec 2, 2020 | Citigroup | downgrade | Buy → Neutral | $4 | 54% |
| Dec 2, 2020 | JMP Securities | downgrade | Market Outperform → Market Perform | $0 | 53% |
| Aug 26, 2020 | Citigroup | maintain | — → Buy | $10 | 54% |
| Jun 18, 2020 | Cantor Fitzgerald | maintain | — → Overweight | $13 | 50% |
| Sep 24, 2019 | Citigroup | maintain | — → Buy | $10 | 54% |
| Sep 4, 2019 | RBC Capital | initiate | — → Outperform | $12 | 55% |
| Nov 15, 2018 | Cantor Fitzgerald | initiate | — → Overweight | $0 | 50% |
| Apr 20, 2018 | Ladenburg Thalmann | initiate | — → Buy | $27 | 45% |
Price Target Trend
Apr 9, 2026 Oct 26, 2026
EPS Estimates
0y —
+1y —
+1q —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days